mTOR Inhibition for Cancer Therapy: Past, Present and Future

Editors: Mita, Monica, Mita, Alain, Rowinsky, Eric K. (Eds.)

  • First book on that topic
  • Input and perspectives by international leaders​
  • Preclinical and clinical data available on the subject have been integrated
  • A dedicated chapter on toxicity profile of mTOR inhibitors
  • Future directions for the development of mTOR inhibitors
see more benefits

Buy this book

eBook $139.00
price for USA (gross)
  • ISBN 978-2-8178-0492-7
  • Digitally watermarked, DRM-free
  • Included format: EPUB, PDF
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover $179.00
price for USA
  • ISBN 978-2-8178-0491-0
  • Free shipping for individuals worldwide
  • Usually dispatched within 3 to 5 business days.
About this book

This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. 

Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation.

About the authors

Monica Mita and Alain Mita are Associate Professors of Medicine and Co-Directors of the Experimental Therapeutics Program at the Samuel Oschin Comprehensive Cancer institute, Cedars-Sinai Medical Center in Los Angeles, CA. Eric Rowinsky is Chief Medical Officer, Head of Research and Development, and Executive Vice President at Stemline Therapeutics, Inc. He is also an Adjunct Professor of Medicine at New York University School of Medicine and a cancer drug development consultant at Oncodrugs.

Table of contents (13 chapters)

  • Targeting mTOR: A Little Bit of History and a Large Future

    Rowinsky, Eric K.

    Pages 1-17

  • The PI3K-mTOR Pathway

    Thomas, Hala Elnakat (et al.)

    Pages 19-45

  • The Evolving Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in Renal Cell Carcinoma

    Tan, Carlyn C. (et al.)

    Pages 47-66

  • The Role of mTOR Inhibitors in Breast Cancer

    Aftimos, Philippe G. (et al.)

    Pages 67-92

  • The Role of mTOR Inhibitors in Neuroendocrine Tumors

    Hendifar, Andrew E. (et al.)

    Pages 93-112

Buy this book

eBook $139.00
price for USA (gross)
  • ISBN 978-2-8178-0492-7
  • Digitally watermarked, DRM-free
  • Included format: EPUB, PDF
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover $179.00
price for USA
  • ISBN 978-2-8178-0491-0
  • Free shipping for individuals worldwide
  • Usually dispatched within 3 to 5 business days.
Loading...

Recommended for you

Loading...

Bibliographic Information

Bibliographic Information
Book Title
mTOR Inhibition for Cancer Therapy: Past, Present and Future
Editors
  • Monica Mita
  • Alain Mita
  • Eric K. Rowinsky
Copyright
2016
Publisher
Springer-Verlag Paris
Copyright Holder
Springer-Verlag France
eBook ISBN
978-2-8178-0492-7
DOI
10.1007/978-2-8178-0492-7
Hardcover ISBN
978-2-8178-0491-0
Edition Number
1
Number of Pages
VI, 300
Topics